Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline

Naoki Aomatsu1, Masakazu Yashiro1,2*, Shinichiro Kashiwagi1, Hidemi Kawajiri1, Tsutomu Takashima1, Masahiko Ohsawa3, Kenichi Wakasa3 and Kosei Hirakawa1

Abstract

Background: Neoadjuvant chemotherapy (NAC) is one of the standard care regimens for patients with resectable early-stage breast cancer. It would be advantageous to determine the chemosensitivity of tumors before initiating NAC. One of the parameters potentially compromising such chemosensitivity would be a hypoxic microenvironment of cancer cells. The aim of this study was thus to clarify the correlation between expression of the hypoxic marker carbonic anhydrase-9 (CA9) and chemosensitivity to NAC as well as prognosis of breast cancer patients.

Methods: A total of 102 patients with resectable early-stage breast cancer was treated with NAC consisting of FEC (5-fluorouracil, epirubicin, and cyclophosphamide) followed by weekly paclitaxel before surgery. Core needle biopsy (CNB) specimens and resected tumors were obtained from all patients before and after NAC, respectively. Chemosensitivity to NAC and the prognostic potential of CA9 expression were evaluated by immunohistochemistry.

Results: CA9 positivity was detected in the CNB specimens from 47 (46%) of 102 patients. The CA9 expression in CNB specimens was significantly correlated with pathological response, lymph node metastasis, and lymph-vascular invasion. Multivariate analysis revealed that the CA9 expression in CNB specimens was an independent predictive factor for pathological response. The Kaplan-Meier survival curve revealed a significant negative correlation (p = 0.013) between the disease-free survival (DFS) and the CA9 expression in resected tissues after NAC. Multivariate regression analyses indicated that the CA9 expression in resected tissues was an independent prognostic factor for DFS.

Conclusions: CA9 expression in CNB specimens is a useful marker for predicting chemosensitivity, and CA9 expression in resected tissue is prognostic of DFS in patients with resectable early-stage breast cancer treated by sequential FEC and weekly paclitaxel prior to resection.

Keywords: Breast cancer, Carbonic anhydrase 9, Neoadjuvant chemotherapy, Predictive marker, Chemosensitivity
complete response (cCR) rate of approximately 60% [10]. In contrast, NAC is ineffective in approximately half of all patients, and many experience toxicity. Therefore, it would be advantageous to identify patients with chemosensitive tumors before initiating NAC, to avoid potential therapy-related complications and an inappropriate delay of surgical treatment.

NAC has numerous advantages, including the provision of pathological response data that can be used as a surrogate marker for long-term clinical outcomes [11,12]. Also, the assessment of responsiveness to NAC allows the evaluation of potential predictive molecular markers for chemosensitivity. Several biological markers, including the estrogen receptor (ER), progesterone receptor (PgR), HER2, Ki-67, p21, p53, Bcl, multi-drug-resistant P-glycoprotein, and topoisomerase 2A, have recently been investigated; however, there exists no clear correlation between the expression of these markers and chemosensitivity after sequential taxane- and anthracycline-based chemotherapies [13-17].

Carbonic anhydrase 9 (CA9) is a cell surface enzyme that catalyzes the reversible hydration of carbon dioxide to bicarbonate and a proton [18] and maintains pericellular pH homeostasis [19,20]. CA 9 is overexpressed in response to tumor hypoxia in many common tumor types [21-24] and plays a critical role in hypoxia-associated tumor acidity [25-27]. Hypoxia-inducible factor-1 α (HIF-1 α) binds to the hypoxia-responsive element present in the promoter regions of CA9 and up-regulates CA9 expression [24,28]. Hypoxia plays an important role in tumor progression and chemoresistance in various types of cancer [29-32]. CA9 has been implicated in the regulation of the micro-environmental pH in tumor hypoxia. In this retrospective study, we examined the correlation between CA9 expression and chemosensitivity to NAC in breast cancer as well as the prognosis of patients.

Methods
Patients
A total of 102 patients with resectable early-stage breast cancer, which was considered to be stage IIA (T2 N0 M0), IIB (T2 N1 M0 or T3 N0 M0), or IIIA (T3 N1 M0), were treated with NAC from 2004 to 2009. Breast cancers were confirmed histopathologically by core needle biopsy (CNB) and were staged by computed tomography and bone scan. The clinicopathologic features of the 102 breast cancers are shown in Additional file 1: Table S1. The clinical stage was based on the TNM Classification of Malignant Tumors, 6th Edition [33]. No patients had evidence of distant metastasis at the time of surgery. All of the cases received neoadjuvant chemotherapy consisting of 4[cycles of 5-fluorouracil (5FU) 500 mg/m², epirubicin 75 or 100 mg/m², and cyclophosphamide 500 mg/m² (FEC) followed by 12 cycles of weekly paclitaxel 80 mg/m² (wPTX). Sixteen of 102 patients showed HER2-positive breast cancer, and were administered weekly trastuzumab with wPTX. Patients underwent mastectomy or breast-conserving surgery after NAC. All patients who underwent breast-conserving surgery were administered postoperative radiotherapy. Overall survival time was set in days as the period from the initiation of NAC. DFS (disease-free survival) was defined as freedom from all local, regional, or distant recurrence. All patients were followed by physical examination, ultrasonography, computed tomography and bone scan. The median follow-up period was 6.2 months. This study was conducted with the approval of the ethical committee of Osaka City University, and written informed consent was obtained from all patients.

Assessment of clinical and pathological responses to NAC
Clinical response of the primary tumor was assessed by ultrasonography, computed tomography, and physical examination after NAC. Clinical responses were classified according to the WHO criteria [34]. After NAC, patients underwent appropriate surgery. The clinical response to preoperative chemotherapy was determined from the two diameters measurable in two dimensions by multiplying the longest diameter by the greatest perpendicular diameter and was classified as follows. Clinical complete response (cCR) was judged as the disappearance of all known disease determined by two observations not less than four weeks apart. Clinical partial response (cPR) was a 50% or greater decrease in total tumor lesions. Clinical no change (cNC) was a less than 50% decrease in total tumor size, without a 25% increase in tumor size. Clinical progressive disease (cPD) was defined as a 25% or greater increase in the tumor size, or the appearance of new lesions. The first two categories, cCR and cPR, were judged as effective. Pathological responses of the tumor and dissected lymph nodes were classified according to the evaluation criteria of the Japanese Breast Cancer Society (JBCS) [35], using a 5 histological-grade scale (Grades 0, 1a, 1b, 2, and 3) as follows: Grade 0, no response or almost no change in cancer cells after treatment; Grade 1, slight response; Grade 1a, mild response, mild change in cancer cells regardless of the area, or marked changes in cancer cells in less than one-third of total cancer cells; Grade 1b, moderate response, marked changes in one-third or more but less than two-thirds of tumor cells; Grade 2, marked response or marked changes in two-thirds or more of tumor cells; and Grade 3, no residual tumor cells, necrosis or disappearance of all tumor cells, or replacement of all cancer cells by granuloma-like and/or fibrous tissue. pCR (pathological complete response) was defined as the complete disappearance of infiltrates, including lymph node infiltrates. Tumors with residual...
ductal carcinoma in situ were included in the pCR group. Marked changes approaching a complete response with only a few remaining cancer cells were classified as near pCR [36,37]. The others were classified in the non-pCR group.

Immunohistochemical examinations
All patients underwent a CNB before NAC, and an operation consisting of mastectomy or conserving surgery with axillary lymph node dissection after NAC at Osaka City University. Tissues from each patient were fixed in buffered formalin and embedded in paraffin. Serial tissue sections of 4 μm thickness were stained with hematoxylin-eosin and used for immunohistochemical staining. Expressions of CA9, estrogen receptor (ER), progesterone receptor (PgR), and HER2 were assessed by immunohistochemistry. After the paraffin sections were deparaffinized, they were heated for 20 min at 105°C by autoclave in Target Retrieval Solution (Dako, Carpinteria, CA). After blocking with 10% goat serum, the slides were incubated with the primary monoclonal antibodies against each of CA9 (clone M75, 1:1000; Novus Biologicals), ER (clone 1D5, dilution 1:80; Dako, Cambridge, UK), PgR (clone PgR636, dilution 1:100; Dako), and HER2 (Hercep Test, Dako) overnight at 4°C. Peroxidase was introduced using a streptavidin conjugate and then peroxidase reactivity was visualized using a DAB solution, followed by counterstaining with hematoxylin.

Immunohistochemical assessment
Immunohistochemical scoring was graded by trained pathologists (Masahiko Ohsawa and Kenichi Wakasa, Department of Diagnostic Pathology). The stroma was excluded from the staining evaluation. All staining was scored by counting the number of positive-stained cells, and was expressed as a percentage of the 1000 tumor cells counted across several representative fields of the section using a standard light microscope equipped with a x 100 square graticule. The reproducibility of counting was assessed by a second investigator. The cut-off for ER positivity and PgR positivity was ≥1% positive tumor cells with nuclear staining. HER2 was graded in four steps according to the accepted scheme: 0, 1+, 2+, 3+. HER2 was considered to be positive if immunostaining was 3+ or if a 2+ result showed gene amplification by fluorescent in situ hybridization. The ER, PR, and HER2 stainings were evaluated as described in previous reports [38]. The CA9 antibody intensely stained the membranes of cancer cells. Scores were applied as follows: score 0, negative staining in all cells; score 1+, weakly positive or focally positive staining in <10% of the cells; score 2+, moderately positive staining covering >10% of the cells; and score 3+, strongly positive staining in >10% of the cells (Figure 1). CA9 expression was considered positive for scores of 2+ or 3+.

Statistical analysis
Statistical analysis was performed using SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). The association between the expression of CA9 and clinicopathological parameters was analyzed with the chi-square test. Binary logistic regression was used for multivariate analyses to identify independent prognostic factors for a pathological complete response. The Kaplan-Meier method was used to estimate the values of DFS. DFS was compared using a log-rank test. The Cox regression model was used for multivariate analysis of prognostic factors. In all of the tests, a p value less than 0.05 was considered to be statistically significant.

Results
Clinicopathological responses of breast cancers to NAC
The cCR rate was 17% (18/102), cPR was 61% (62/102), cNC was 20% (20/102), and cPD was 2% (2/102). Therefore, the clinical responders (cCR + cPR) made up 78% (80/102) of the patients. The pathological response was evaluated using resected tissue after NAC. Of the tumors investigated, 12% (12/102) were histological response grade 1a, 33% (34/102) were grade 1b, 20% (20/102) were grade 2a, 16% (16/102) were grade 2b, and 20% (20/102) were grade 3. Patients were classified into pathologic responders (grade 2 and 3; 55% of all patients) and non-responders (grade 1; 45%) according to the grade of the tumor. The pCR rate was 29% (30/102). The DFS of pathologic non-responders was significantly (p = 0.01) shorter than that of pathologic responders, while no significant difference in DFS was found between clinical non-responders and clinical responders (Figure 2).

Association between clinicopathological parameters and CA9 expression in CNB specimens
The CA9 expression of primary breast tumors before NAC was analyzed using CNB specimens. Of the 102 breast cancer patients, 47 patients (46%) had CA9-positive breast tumors, while 55 (54%) had CA9-negative tumors. Table 1 shows the correlation between clinicopathological parameters and CA9 expression in breast cancers. The CA9 expression in CNB specimens was significantly correlated with lymph node metastasis (70%, p = 0.001) and lymphatic invasion (69%, p = 0.003). The pCR rate of CA9-positive tumors (23%, 7/30) was significantly lower (p = 0.003) than that of CA9-negative tumors (77%, 23/30). The pathological non-responder tumors showed significantly more frequent CA9 expression than the pathological responder tumors (p < 0.001). Clinical response (cCR + cPR) was not associated with CA9 expression (p = 0.062). Recurrent tumors were observed in 28 of 102 patients. CA9 expression was significantly more frequent (p < 0.001) in patients with recurrent tumors (79%, 22/28) than in those with non-recurrent tumors (34%, 25/74).
There was no significant association between CA9 expression and other clinicopathological factors.

The correlation between the pCR and the pathological or clinical response.
We examined the correlation between the pathological response (pCR vs non-pCR) and pathological or clinical response (Table 2). A pathological response was significantly (p < 0.001) associated with pCR, and a clinical response was also significantly (p = 0.018) associated with pCR.

Association between CA9 and pathological complete response in CNB specimens
Univariate analysis revealed that the expressions of CA9, ER, and PgR in CNB specimens were significantly associated with pCR. There was no significant association between pCR and the other clinicopathological factors. Multivariate analysis revealed that only CA9 expression was significantly associated with pCR (Table 3).

Correlation between clinicopathological parameters and disease-free survival
CA9 expression of breast tumors was analyzed using both CNB specimens and resected tissues. Since 30 of the 102 breast tumors showed a pathological complete response, these cases were excluded from the evaluation of CA9 expression. CA9 expression was therefore examined in 72 resected tissues after NAC. DFS in patients with CA9-positive tumors was significantly shorter than that in those with CA9-negative tumors in both samples (CNB specimens and resected tissues) (Figure 3). Univariate analysis
revealed that CA9 expression in CNB specimens, CA9 expression in resected tissues, tumor size, lymph node status, and pathological response were significantly associated with DFS. There was no significant association between DFS and clinical response. Multivariate regression analyses indicated that CA9 expression in resected tissues after NAC was an independent prognostic factor for DFS (Table 4).

**Table 1 Correlations between CA9 expression and clinicopathological parameters in CNB of 102 primary breast cancers**

| Parameter                  | Positive (n = 47) | Negative (n = 55) | p-value |
|----------------------------|------------------|-------------------|---------|
| Age                        |                  |                   |         |
| ≥55                        | 21 (42%)         | 29 (58%)          |         |
| <55                        | 26 (50%)         | 26 (50%)          | 0.418   |
| Menopause                  |                  |                   |         |
| Positive                   | 31 (44%)         | 40 (56%)          |         |
| Negative                   | 16 (52%)         | 15 (48%)          | 0.459   |
| Intrinsic subtype          |                  |                   |         |
| Luminal                    | 22 (48%)         | 24 (52%)          |         |
| Luminal-HER                | 4 (50%)          | 4 (50%)           |         |
| HER2                       | 4 (24%)          | 13 (76%)          | 0.209   |
| Triple-negative            | 17 (55%)         | 14 (45%)          |         |
| Tumor size                 |                  |                   |         |
| ≥ 4 cm                     | 12 (67%)         | 6 (33%)           |         |
| < 4 cm                     | 35 (42%)         | 49 (58%)          | 0.053   |
| Lymph node status          |                  |                   |         |
| Positive                   | 23 (70%)         | 10 (30%)          |         |
| Negative                   | 24 (35%)         | 45 (65%)          | 0.001   |
| Lymph-vascular invasion    |                  |                   |         |
| Positive                   | 20 (69%)         | 9 (31%)           |         |
| Negative                   | 27 (37%)         | 46 (63%)          | 0.003   |
| Nuclear grade (NG)         |                  |                   |         |
| NG1                        | 32 (43%)         | 42 (57%)          |         |
| NG 2&3                     | 15 (54%)         | 13 (46%)          | 0.350   |
| Pathological response      |                  |                   |         |
| pCR                        | 7 (23%)          | 23 (77%)          |         |
| Non-pCR                    | 40 (56%)         | 32 (44%)          | 0.003   |
| Responder (histological grade 2&3) | 16 (29%) | 40 (71%) |         |
| non-Responder (histological grade 1) | 31 (67%) | 15 (33%) | <0.001 |
| Clinical response          |                  |                   |         |
| Responder (cCR + cPR)      | 33 (41%)         | 47 (59%)          |         |
| non-Responder (cNC + cPD)  | 14 (64%)         | 8 (36%)           | 0.062   |
| Recurrence                 |                  |                   |         |
| Yes                        | 22 (79%)         | 6 (21%)           |         |
| No                         | 25 (34%)         | 49 (66%)          | <0.001  |

**Discussion**

In recent years, NAC has been adopted as one of the standard care regimens for primary resectable early-stage breast cancer. In such cases, the NAC generally consists of an anthracycline-containing regimen and taxane [4,5]. The evaluation of the tumor response to NAC is important to determine the appropriate post-operative chemotherapeutic regimen for patients with recurrent
tumors. There are various systems for classifying the survival response and pathological response in neoadjuvant trials—i.e., the cTMN, Fisher’s, Chevailler’s, and JBCS systems—and all of these have been shown to yield basically comparable results [39]. In this study, we used the WHO and JBCS classifications as the therapeutic response criteria. The pCR rate was 29% (30/102), and the response rate was 78% (80/102). These response rates were similar to those previously reported [6,9,10].

The correlation between chemosensitivity and survival remains controversial. Some papers have reported that the prognostic factors included the clinical and pathological response to primary chemotherapy. On the other hand, at least one paper has reported that response classifications were inadequate as prognostic markers of the long-term outcome after NAC [39]. Our data indicated that clinical response was not a significant predictor of DFS. Although clinical examination provides approximate indicators of chemotherapy responses, histopathologic examination of specimens after chemotherapy is important to evaluate the accurate response or the prognosis [40-43]. A tumor diagnosed as showing a complete clinical response sometimes retains residual carcinoma cells by microscopic examination; conversely, a palpable residual mass may show fibrosis without cancer cells [42,43]. These findings might explain why the association

| Parameter | Univariate analysis | Multivariate analysis |
|-----------|--------------------|----------------------|
| CA9 expression in CNB | | |
| positive vs negative | 0.24 | 0.09-0.63 | 0.041 | 0.21 | 0.07-0.59 | 0.003 |
| ER | | |
| positive vs negative | 0.24 | 0.10-0.61 | 0.002 | 0.23 | 0.02-2.37 | 0.219 |
| PgR | | |
| positive vs negative | 0.22 | 0.08-0.61 | 0.004 | 0.36 | 0.10-1.30 | 0.120 |
| HER2 | | |
| positive vs negative | 1.75 | 0.68-4.48 | 0.244 | | |
| Molecular subtypes | | |
| HR+/HER2- vs others | 0.33 | 0.13-0.83 | 0.018 | 1.78 | 0.18-17.44 | 0.622 |
| HR-/HER2+ vs others | 0.02 | 0.01-2999894 | 0.728 | | |
| HR-/HER2+ vs others | 1.75 | 0.68-4.48 | 0.244 | | |
| HR-/HER2- vs others | 1.17 | 0.93-1.46 | 0.176 | | |
| Age | | |
| ≥55 vs <55 | 0.88 | 0.37-2.05 | 0.759 | | |
| Menopause | | |
| positive vs negative | 0.82 | 0.33-2.05 | 0.677 | | |
| Tumor size | | |
| ≥4 cm vs <4 cm | 0.64 | 0.19-2.12 | 0.463 | | |
| Lymph node status | | |
| positive vs negative | 4.33 | 0.93-20.1 | 0.061 | | |
between clinical response and DFS was more less statistically significant than that between pathological response and DFS in our study.

Our data indicated that pathological response was a significant predictor of the DFS. In this study, FEC followed by wPTX was the only NAC regimen used for patients with resectable early-stage breast cancer. However, the variety of chemotherapy regimens used as NAC in previous reports might have been a factor in producing these inconsistent results.

CA9, a hypoxia-associated endogenous protein, has been implicated in the regulation of the hypoxic microenvironment [44,45]. CA9 is considered to be one of the cellular biomarkers of hypoxic regions in solid tumors. In the present analysis, CA9 was positive in CNB specimens from 47 (46%) of 102 patients, similar to the ratio

| Parameter | Univariate analysis | Multivariate analysis |
|-----------|---------------------|----------------------|
|           | Odd ratio | 95% CI | p value | Odd ratio | 95% CI | p value |
| CA9 expression in CNB specimens | | | | | |
| positive vs negative | 4.44 | 1.80-10.9 | 0.001 | 2.32 | 0.88-6.08 | 0.089 |
| CA9 expression in resected tissues | | | | | |
| positive vs negative | 2.63 | 1.21-5.70 | 0.014 | 2.39 | 1.04-5.49 | 0.041 |
| Tumor size | | | | | |
| ≥ 4 cm vs < 4 cm | 2.46 | 1.11-5.45 | 0.026 | 1.61 | 0.65-3.97 | 0.302 |
| Lymph node status | | | | | |
| N1-3 vs N0 | 3.00 | 1.42-6.35 | 0.004 | 0.97 | 0.38-2.47 | 0.955 |
| Lymph-vascular invasion | | | | | |
| positive vs negative | 4.22 | 1.99-8.92 | <0.001 | 2.75 | 1.11-6.62 | 0.028 |
| ER | | | | | |
| positive vs negative | 0.91 | 0.43-1.94 | 0.807 | | | |
| PgR | | | | | |
| positive vs negative | 0.95 | 0.45-2.02 | 0.905 | | | |
| HER2 | | | | | |
| positive vs negative | 1.36 | 0.59-3.11 | 0.46 | | | |
| Clinical response | | | | | |
| Responder vs non-responder | 0.88 | 0.37-2.08 | 0.78 | | | |
| Pathological response | | | | | |
| Responder vs non-responder | 0.29 | 0.12-0.67 | 0.004 | 1.03 | 0.38-2.78 | 0.953 |
| pCR vs non-pCR | 0.19 | 0.45-0.81 | 0.024 | 1.34 | 0.27-6.62 | 0.722 |
in a previous study [46]. CA9 expression was significantly associated with lymph node status and lymph-vascular invasion. CA9 has been shown to maintain the survival of breast tumor cells under hypoxic conditions [47]. Breast cancer cells under hypoxic conditions might be associated with aggressive tumor phenotypes, which may indicate a poor prognosis for patients with CA9-positive breast cancer, as suggested in previous studies [29,30,48-50].

Tan et al. reported that CA9 in basal-like breast tumors was associated with resistance to chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or adriamycin and cyclophosphamide (AC)) and poor prognosis [30]. In our present analysis of 31 triple-negative breast cancers, the DFS of patients with CA9-positive tumors was significantly shorter (p = 0.015) than that of patients with CA9-negative tumors (Additional file 2: Figure S1). The chemosensitivity of triple-negative breast cancer patients with CA9 was significantly lower than that of the CA9-negative cases (Additional file 1: Table S2). CA9 might be a useful biomarker for chemotherapy in triple-negative breast cancer. Supuran and colleagues found that selective CA9 inhibitors inhibited cell migration and spreading of breast cancer cells in the absence of oxygen, suggesting that CA9 is a pivotal target for antitumor therapy in patients with breast carcinoma [25,51]. These findings suggest that CA9 inhibitors followed by wPTX chemotherapy might be useful in cases of breast carcinoma with resistance to FEC.

Biological markers predicting chemosensitivity have been evaluated in several studies, but there is still no clinically useful marker. ER- or PR-positive patients showed lower pCR rates after NAC than ER- or PR-negative patients. The pCR rate of CA9-positive tumors in CNB specimens was significantly lower than that of CA9-negative tumors. Multivariate analysis revealed that CA9 expression before NAC was an independent predictive factor for pCR. An extensive hypoxic microenvironment as determined by CA9 expression in breast cancer might play a significant role in the resistance to chemotherapy. These results may indicate that CA9 expression in CNB specimens is a useful marker for predicting chemosensitivity to NAC.

We also examined the correlation of CA9 expression between CNB tissues and resected tissues in the 72 patients. Although no significant correlation of CA9 staining was observed between the two groups, CA9 expression in resected tissues showed a tendency (p = 0.081) toward association with that in CNB tissues (Additional file 1: Table S3). CA9 expression after NAC (67%) was higher than that before NAC (46%). CA9-positive cells were observed more frequently in tumor specimens than in CNB specimens. Eleven of 32 patients with CA9-negative tumors before NAC were found to have CA9-positive tumors after NAC. NAC was thus effective in reducing CA9-negative cells, and resulted in an increase in hypoxic CA9-positive cells. Twenty-three of 55 patients with CA9-negative tumors before NAC achieved pCR, and could not be enrolled in the CA9 expression analysis because there was no tumor involvement detected in the resected tissues. These changes in CA9 expression before and after NAC might be one of the reasons for the lack of a significant correlation between the CA9 expression in CNB tissues and that in resected tissues.

CA9 expression in resected tissues after NAC was correlated with both prognosis and recurrence. In addition, multivariate regression analyses indicated that the CA9 expression level after NAC was an independent prognostic factor for DFS. Thus, CA9 expression after NAC may be a clinically informative prognostic marker for breast cancer patients treated with NAC. On the other hand, CA9 expression before NAC in CNB specimens may be a useful surrogate marker for predicting chemosensitivity. Our results indicate that the hypoxic marker CA9 in CNB specimens could be used to predict chemosensitivity, and that high expression of CA9 in resected tissue is correlated with worse outcomes in patients treated with FEC followed by wPTX chemotherapy.

Conclusion

Hypoxic microenvironment as determined by CA9 expression in breast cancer might play a significant role in the resistance to chemotherapy, which indicates that CA9 expression in CNB specimens is a useful marker for predicting chemosensitivity to NAC. CA9 expression in resected tissue is prognostic of DFS in patients with resectable early-stage breast cancer treated by sequential FEC and weekly paclitaxel prior to resection.

Additional files

Additional file 1: Table S1. Clinicopathologic features of 102 breast cancers. Table S2. Correlations between CA9 expression and chemosensitivity in 31 triple-negative breast cancers. Table S3. Correlation of CA9 expression before NAC to that after NAC in the 72 patients who did not achieve pCR.

Additional file 2: Figure S1. Disease-free survival of patients based on CA-9 expression in 31 cases of triple-negative breast cancer. Among the cases of triple-negative breast cancer, the DFS of patients with CA9-positive tumors was significantly shorter (p =0.015) than that of patients with CA9-negative tumors. (TIFF 25 kb)

Abbreviations

CR: Complete response; CNB: Core needle biopsy; CSCs: Cancer stem cells; DFS: Disease-free survival; ER: Estrogen receptor; FEC: 5-fluorouracil + epirubicin + cyclophosphamide; HER2: Human epidermal growth factor receptor 2; IHC: Immunohistochemistry; NAC: Neoadjuvant chemotherapy; NC: No change; OS: Overall survival; PgR: Progesterone receptor; PR: Partial response; PD: Progressive disease; pCR: Pathologic complete response.
Acknowledgement

The study was supported in part by Grants-in-Aid for Scientific Research (KAKENHI, Nos. 20591573, 22390262, and 23390329) from the Ministry of Education, Science, Sports, Culture and Technology of Japan.

Author details

1 Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan. 2 Oncology Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. 3 Department of Diagnostic Pathology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, Japan.

Received: 5 March 2013 Accepted: 29 May 2014

References

1. Mayer EL, Carey LA, Burstein HJ: Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res 2009, 11(5):110.

2. Sachedina I, Grossbard ML, Chahida M, Feldman S, Ghesani M, Blum RH: Primary systemic therapy of breast cancer. Oncologist 2006, 11(6):574–589.

3. Fisher B, Brown A, Mamounas E, Winer EP, Robidoux A, Margolese RG.发差的, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Hoefn AL, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol 1997, 15(7):2483–2493.

4. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr 2001, 30:96–102.

5. Bear HD, Anderson S, Brown A, Mamounas EP, Fisher B, Margolese RG, Robidoux A, Theoret H, Soran A, Wickerham DL, Wolmark N: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2003, 21(2):4165–4174.

6. Smith KC, Heys SD, Hutchison AW, Miller JD, Payne S, Gilbert FJ, Ah-See AK, Ermin O, Walker LG, Sarkar TK, Casini A, Kettmann R, Pastorek J: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20(14):1456–1466.

7. Goldshirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.Ann Oncol 2007, 18(7):1133–1144.

8. Fisher CS, Ma CK, Gillanders WE, Aft RL, Ebeler TJ, Gao F, Mangenhauer JA: Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol 2012, 19(12):235–238.

9. Chollet P, Amat S, Cure H, de Latour M, Le Boudec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F: Prognostic significance of a complete pathologic response after induction chemotherapy in operable breast cancer. Br J Cancer 2002, 86(7):1041–1046.

10. Jones RL, Smith IC: Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol 2006, 7(10):869–874.

11. Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutchison AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Marsi JL: Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-continental oncology group study. J Clin Oncol 2005, 23(13):2988–2995.

12. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2006, 24(12):1921–2007.

13. Estevez LG, Cuevas JM, Antonia A, Florian J, Lopez-Vega JM, Velasco A, Lobo F, Herrero A, Fortes J: Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2005, 11(2):686–692.

14. Chutthapisit S, Eremin JM, El-Sheemy M, Eremin O: Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon 2006, 4(4):211–219.

15. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN: Breast cancer biomarkers. Adv Clin Chem 2005, 4099–125.

16. Colleoni M, Viale G, Zahrieb D, Pruneti G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nole F, Peruzzi G, Goldhirsh A: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004, 10(19):6622–6628.

17. Rody A, Kann T, Gatje R, Ahir A, Solbach C, Koursis K, Munner WD, Erks EA, Schubert E, Holthuis U, Areal HU, Kaufmann M: Gene expression profiling of breast cancer patients treated with doxorubicin, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 2007, 16(1):83–96.

18. Liao SY, Brewer C, Zavada J, Pastorek J, Pastorekova S, Manetta A, Berman ML, DiSaia PJ, Stanbridge EJ: Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. The American journal of pathology 1994, 145(3):598–609.

19. Pastorek J, Pastorekova S, Callebaut I, Morson JP, Zelink V, Opavsky R, Zafirovski M, Liao SY, Portetelle D, Stanbridge EJ: Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrate and a putative helix-loop-helix DNA binding segment. Oncogene 1994, 9(10):2877–2888.

20. Opavsky R, Pastorekova S, Zelink V, Gabidulinaova A, Stanbridge EJ, Zavada J, Kettmann R, Pastorek J: Human MN/CA9 gene, a novel member of the carbonic anhydrate family: structure and exon to protein domain relationships. Genomics 1996, 33(3):480–487.

21. Chen CL, Chu JY, Su WC, Huang SC, Lee WY: Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Archiv: an international journal of pathology 2010, 457(1):53–61.

22. Shin KH, Diaz-Gonzalez JA, Russell JC, Chen Q, Burgman P, Li YF, Ling CC: Detecting changes in tumor hypoxia with carbonic anhydrate IX and pimonidazole. Cancer biology & therapy 2007, 6(1):70–75.

23. Russell J, Caplin S, Burke SA, Web B, Yang XM, Ling CC: Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Biol Phys 2003, 57(2):1177–1186.

24. Ivanov S, Liao SY, Ivanova DA, Danilkovich-Vlagova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Wiederh A, Sly W, Lerman MI, Stanbridge EJ: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. The American journal of pathology 2001, 158(3):905–919.

25. Neri D, Supuran CT: Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011, 10(10):767–777.

26. Svasts V, Hulikova A, Zatovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafera A, Supuran CT, Pastorek J, Pastorekova S: Hypoxia activates the capacity of tumor-associated carbonic anhydrate IX to acidify extracellular pH. FEBS Lett 2004, 579(15):443–445.

27. Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL: New insights into the physiological role of carbonic anhydrate IX in tumour pH regulation. Oncogene 2010, 29(50):6599–6652.

28. Grabmair K, Adw MC, Verheugen GW, Schalken JA, Oosterwijk J: Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004, 23(33):5624–5631.
Potter CP, Harris AL: Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003, 89(1):2–7.